Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Emmaus Life Sciences, Inc. (EMMA)

0.35   -0.04 (-10.26%) 12-05 11:36
Open: 0.35 Pre. Close: 0.39
High: 0.35 Low: 0.35
Volume: 7,100 Market Cap: 17(M)

Technical analysis

as of: 2022-12-06 7:47:34 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.48     One year: 0.58
Support: Support1: 0.28    Support2: 0.23
Resistance: Resistance1: 0.41    Resistance2: 0.5
Pivot: 0.36
Moving Average: MA(5): 0.38     MA(20): 0.37
MA(100): 0.31     MA(250): 0.72
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 42.4     %D(3): 50.1
RSI: RSI(14): 49.7
52-week: High: 1.75  Low: 0.07
Average Vol(K): 3-Month: 41 (K)  10-Days: 8 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EMMA ] has closed above bottom band by 39.4%. Bollinger Bands are 16.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.35 - 0.35 0.35 - 0.35
Low: 0.34 - 0.35 0.35 - 0.35
Close: 0.35 - 0.35 0.35 - 0.35

Company Description

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

Headline News

Tue, 06 Dec 2022
Emma Scully Gallery Champions "Female Spirit" - HYPEBEAST

Tue, 06 Dec 2022
Emma Katherine DeFilippo (Kathy) | News, Sports, Jobs - Nashua Telegraph

Mon, 05 Dec 2022
Emma Corrin’s gender identity represents ‘embrace of many different parts’ - KXLY Spokane

Mon, 05 Dec 2022
Orlando review – Emma Corrin is glorious in a giddy, heartfelt show - The Guardian

Mon, 05 Dec 2022
Welp family holds 2nd annual “Embracing Emma” toy drive -

Mon, 05 Dec 2022
Emma Chamberlain on Her Favorite Winter Fashion Trends & the Perfect Chamberlain Coffee Gifts - E! NEWS

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  PNK
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 50 (M)
Shares Float 29 (M)
% Held by Insiders 38.7 (%)
% Held by Institutions 0 (%)
Shares Short 41 (K)
Shares Short P.Month 34 (K)

Stock Financials

EPS -0.19
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.76
Profit Margin (%) -114.3
Operating Margin (%) -65.5
Return on Assets (ttm) -12.4
Return on Equity (ttm) 0
Qtrly Rev. Growth -14.4
Gross Profit (p.s.) 0.34
Sales Per Share 0.31
EBITDA (p.s.) -0.21
Qtrly Earnings Growth 0
Operating Cash Flow -6 (M)
Levered Free Cash Flow -4 (M)

Stock Valuations

PE Ratio -1.91
PEG Ratio 0
Price to Book value -0.47
Price to Sales 1.12
Price to Cash Flow -2.96

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-07-17
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.